Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07111325

Safety and Preliminary Efficacy of iEVs Injection in Treating Lateral Epicondylitis of Humerus

Evaluate the safety and preliminary efficacy of human induced pluripotent stem cell-derived extracellular vesicle (iEV) injection in the treatment of lateral epicondylitis of the humerus.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Shanghai Sixth hospital

Shanghai, Shanghai Municipality, 200000, China

Location status: Recruiting

Location contact

Jian Ding, Dr.

CONTACT

[email protected]

+86 021 64369181

About this study

Lateral epicondylitis refers to pain at the lateral epicondyle of the humerus caused by chronic traumatic tendinopathic changes in the origin and insertion of the common extensor tendon on the lateral side of the elbow joint, which result from long-term and repeated loading.

This randomized controlled study aims to observe whether extracellular vesicles derived from human induced pluripotent stem cells (iEVs) can promote the improvement of inflammatory status in injured extensor tendons and alleviate clinical symptoms. The study design will evaluate the efficacy by assessing changes in patients' pain, grip strength, and elbow joint function after treatment with the injection, and compare the efficacy with that of the control groups.

This is an interventional, single-center clinical study. The study plans to adopt a block randomization method without stratification. A randomization list will be generated separately for each research center by a computer, and participants will be randomly assigned to the experimental group, positive control group, and negative control group. There will be 6-12 cases in the experimental group, and 3-6 cases in each of the two control groups.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with lateral epicondylitis by clinical symptom examination and MRI or ultrasound, without obvious tendon tear;
  • Unilateral lateral elbow pain lasting for more than 12 weeks;
  • Pain is provoked by at least 2 of the following methods, with a pain VAS score exceeding 3: maximum grip strength, palpation of the lateral epicondyle of the elbow and surrounding area, resisted dorsiflexion of the wrist or middle finger, or stretching of the forearm extensor muscles under a pain-free grip state;
  • Having received physical therapy or non-steroidal anti-inflammatory drug treatment with poor efficacy;
  • Individuals with independent behavioral capacity, who have signed the informed consent form themselves.

Exclusion criteria

  • Complaints of ipsilateral muscle pain caused by other reasons in the past 6 months;
  • Presence of ipsilateral neurogenic, inflammatory, or systemic joint diseases;
  • A history of previous lateral epicondylitis (LET) surgery in the past 6 months;
  • Subjects deemed unsuitable for participating in the trial due to other conditions, as judged by the researcher;
  • MRI showing that the injury has involved the lateral collateral ligament, with concurrent cartilage damage.

Treatment and study plan

iEV

Biological

induced pluripotent stem cell-derived extracellular vesicles

PRP

Biological

PRP injection

Immobilization

Other

immobilization

Primary outcomes

  1. Assess changes in pain levels using a Visual Analogue Scale (VAS)

    Time frame: From enrollment to the end of treatment at 12 weeks

    Assess changes in pain levels using the Visual Analogue Scale (VAS). The scale ranges from 0 (no pain) to 10 (the most severe pain), where a higher score indicates more severe pain (worse outcome) and a lower score indicates less severe pain (better outcome).

  2. Evaluate changes in functional outcomes through patient-rated tennis elbow assessments (PRTEE)

    Time frame: From enrollment to the end of treatment at 12 weeks

    To assess changes in functional outcomes, the Patient-Rated Tennis Elbow Evaluation (PRTEE) is utilized. This scale encompasses 15 items, divided into two dimensions: the pain dimension (5 items) and the function dimension (10 items). It uses a 0-10 scoring system, where a higher total score indicates more severe functional impairment (worse outcome), and a lower total score indicates less severe functional impairment (better outcome).

  3. Assess changes in functional outcomes using the Mayo Elbow Performance Score (MEPS)

    Time frame: From enrollment to the end of treatment at 12 weeks

    To assess changes in elbow function, the Mayo Elbow Performance Score (MEPS) is employed. This scale ranges from 0 to 100, where a higher score indicates better elbow function (better outcome) and a lower score indicates worse elbow function (worse outcome).

  4. Incidence of adverse events

    Time frame: From enrollment to the end of treatment at 12 weeks

Secondary outcomes

  1. Changes in the results of the SF-36 Quality of Life Questionnaire

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Changes in functional outcomes assessed by the Subjective Elbow Value (SEV)

    Time frame: From enrollment to the end of treatment at 12 weeks

  3. MRI imaging assessment at 3 months after injection

    Time frame: From enrollment to the end of treatment at 12 weeks

Sponsors and collaborators

Lead sponsor

Shanghai 6th People's Hospital

Other

Registry information

Official study title

A Clinical Trial Study Evaluating the Safety and Preliminary Efficacy of Human Induced Pluripotent Stem Cell-derived Extracellular Vesicles (iEVs) Injection for the Treatment of Lateral Epicondylitis of the Humerus

Acronym: iEVs

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Aug 8, 2025
Registry last updated
Aug 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.